0
Skip to Content
Optimo Capital
Optimo Capital
About
Pre-IPOs
Research Services
Research Client List
Research Library
Daily Analysis
Contact & Sign Up
Optimo Capital
Optimo Capital
About
Pre-IPOs
Research Services
Research Client List
Research Library
Daily Analysis
Contact & Sign Up
About
Pre-IPOs
Folder: Equity Research
Back
Research Services
Research Client List
Research Library
Daily Analysis
Contact & Sign Up
Volex - on course for FTSE 250 after profit upgrade and 28% revenue growth
Ryan McCallum 25/08/2026 Ryan McCallum 25/08/2026

Volex - on course for FTSE 250 after profit upgrade and 28% revenue growth

Volex expects its FY2027 underlying operating profit to be ahead of current market expectations..

Read More

ENQUIRY

Please register your interest below and a member of our team will be in contact.

Thank you!

CONTACT

Email us at: info@optimocapital.co.uk

Call us on 07711 828 771

Follow us on social media

LEGAL

Privacy Policy

Disclosures, disclaimers & risk warnings

This website acts as a portal for both Optimo Capital Limited and Optimo Research Ltd, two separate companies registered with Companies House in the UK which share a majority shareholder.

Optimo Capital Limited is a private limited company (Companies House number 13017605) with its registered office at 124 City Road, London, EC1V 2NX. Optimo Capital Limited undertakes activities which are not regulated by the Financial Conduct Authority, namely acting as an introducer between companies and potential providers of capital.

Optimo Research Ltd is a private limited company (Companies House number 06427125) with its registered office at 124 City Road, London, EC1V 2NX. Optimo Research Ltd offers professional equity research services to growth companies and the companies covered pay a fee in order for this research to be made available. Optimo Research Ltd is authorised & regulated by the Financial Conduct Authority. FRN No. 768993.

Nothing in our research reports should be construed as an offer or the solicitation of an offer to buy or sell securities by us and, as we have no knowledge of your individual situation and circumstances, you should not make any investment decision without consulting a fully qualified financial adviser. Research notes do not constitute advice and your capital is at risk by investing in the financial instruments issued by the companies discussed. For full disclosures, disclaimers and risk warnings click here.